T-19 Inc. Proud to Announce Tubercin Inventor and Scientific Advisor Dr. Tai-Ho Chung Ph.D. M.D. Has Been Reappointed World Health Organization Immunological Research Director
HONOLULU--(BW HealthWire)--March 22, 2002--T-19 Incorporated is proud to announce that Tubercin inventor and scientific advisor Dr. Tai-Ho Chung Ph.D. M.D. has been reappointed Director of the World Health Organization (WHO) Collaborating Centre for Immunological Research on the Prevention and Control of Viral Hepatitis and its Related Disease.
T-19 has entered into a Letter of Intent to be acquired by LCS Golf Inc (OTCBB:LCSG). LCS Golf President Michael Mitchell M.D. says, This appointment furthers the credibility and our excitement concerning this pending acquisition.
Over two thousand stage 3 and 4 cancer patients have been treated with an injectable version of Tubercin under strict clinical settings in South Korea at the oldest and very prestigious university hospital, Kyungpook National University Medical School, in Taegu, Korea. Today approximately 40% of these 2000 terminal Cancer patients were positively impacted and a significant number has remained cancer free within a 20 year duration. Dr. Tai-Ho Chung, the inventor of Tubercin T-5, has published his findings over the last seventeen years in Korean Medical Journals. Dr. Tai-Ho Chung was the former Medical School dean and is currently the Director of the World Health Organization (WHO) Collaborating Centre for Immunological Research on the Prevention and Control of Viral Hepatitis and its Related Disease situated at the Kyungpook National University, Taegu, Korea.
T-19 Incorporated is preparing a version of Tubercin called T-19 which is to be ingested as a nasal spray.
More information can be found at: tubercin.com.
CONTACT: T-19 Incorporated, Honolulu
Eric Schopfer, 866/523-5800 |
